Legis Daily

CHANGE Act of 2021

USA117th CongressHR-3354| House 
| Updated: 5/20/2021
Linda T. Sánchez

Linda T. Sánchez

Democratic Representative

California

Cosponsors (45)
Val Butler Demings (Democratic)Tom Cole (Republican)Mikie Sherrill (Democratic)Raúl M. Grijalva (Democratic)Mark Pocan (Democratic)Joyce Beatty (Democratic)Darin LaHood (Republican)David Scott (Democratic)Dina Titus (Democratic)Michael F. Doyle (Democratic)Madeleine Dean (Democratic)Donald M. Payne (Democratic)Thomas R. Suozzi (Democratic)Haley M. Stevens (Democratic)Anthony G. Brown (Democratic)Lucille Roybal-Allard (Democratic)Peter A. DeFazio (Democratic)Ro Khanna (Democratic)Maria Elvira Salazar (Republican)Greg Stanton (Democratic)Alan S. Lowenthal (Democratic)Ann M. Kuster (Democratic)Don Bacon (Republican)Fred Upton (Republican)Doris O. Matsui (Democratic)Filemon Vela (Democratic)Glenn Grothman (Republican)Mark Takano (Democratic)Eleanor Holmes Norton (Democratic)Jamie Raskin (Democratic)Cynthia Axne (Democratic)James P. McGovern (Democratic)Maxine Waters (Democratic)William R. Keating (Democratic)Marie Newman (Democratic)Adam Kinzinger (Republican)Peter Welch (Democratic)Brian K. Fitzpatrick (Republican)Bill Posey (Republican)Nanette Diaz Barragán (Democratic)Teresa Leger Fernandez (Democratic)Rashida Tlaib (Democratic)Grace F. Napolitano (Democratic)Susan Wild (Democratic)Judy Chu (Democratic)

Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2021 or the CHANGE Act of 2021 This bill modifies the requirements under Medicare for diagnosing and treating Alzheimer's disease and other cognitive impairments in older adults. Specifically, the bill expands the cognitive impairment detection benefit during annual wellness visits to require the use of validated detection tools and documentation of the results in the patient's medical record. Further, when a cognitive impairment is detected, the patient must be referred to an appropriate diagnostic service provider and other specified supports. Additionally, the Centers for Medicare & Medicaid Services must implement Medicare policies that increase the identification and response to patients' Alzheimer's disease risk factors and incentivize providers to utilize high-quality cognitive impairment diagnosis practices. The Government Accountability Office also must conduct a study of policies that may accelerate progress in Alzheimer's disease research and enhance the quality of care for individuals diagnosed with Alzheimer's disease.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-2283
CHANGE Act of 2019
May 19, 2021
Introduced in House
May 19, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 20, 2021
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 116-2283
    CHANGE Act of 2019


  • May 19, 2021
    Introduced in House


  • May 19, 2021
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • May 20, 2021
    Referred to the Subcommittee on Health.

Health

Related Bills

  • S 117-1692: Concentrating on High-Value Alzheimer’s Needs to Get to an End (CHANGE) Act of 2021
AgingCongressional oversightGovernment studies and investigationsHealth care costs and insuranceHealth care qualityHealth information and medical recordsHealth promotion and preventive careMedical researchMedical tests and diagnostic methodsMedicareNeurological disordersPublic-private cooperationResearch administration and funding

CHANGE Act of 2021

USA117th CongressHR-3354| House 
| Updated: 5/20/2021
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2021 or the CHANGE Act of 2021 This bill modifies the requirements under Medicare for diagnosing and treating Alzheimer's disease and other cognitive impairments in older adults. Specifically, the bill expands the cognitive impairment detection benefit during annual wellness visits to require the use of validated detection tools and documentation of the results in the patient's medical record. Further, when a cognitive impairment is detected, the patient must be referred to an appropriate diagnostic service provider and other specified supports. Additionally, the Centers for Medicare & Medicaid Services must implement Medicare policies that increase the identification and response to patients' Alzheimer's disease risk factors and incentivize providers to utilize high-quality cognitive impairment diagnosis practices. The Government Accountability Office also must conduct a study of policies that may accelerate progress in Alzheimer's disease research and enhance the quality of care for individuals diagnosed with Alzheimer's disease.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-2283
CHANGE Act of 2019
May 19, 2021
Introduced in House
May 19, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 20, 2021
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 116-2283
    CHANGE Act of 2019


  • May 19, 2021
    Introduced in House


  • May 19, 2021
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • May 20, 2021
    Referred to the Subcommittee on Health.
Linda T. Sánchez

Linda T. Sánchez

Democratic Representative

California

Cosponsors (45)
Val Butler Demings (Democratic)Tom Cole (Republican)Mikie Sherrill (Democratic)Raúl M. Grijalva (Democratic)Mark Pocan (Democratic)Joyce Beatty (Democratic)Darin LaHood (Republican)David Scott (Democratic)Dina Titus (Democratic)Michael F. Doyle (Democratic)Madeleine Dean (Democratic)Donald M. Payne (Democratic)Thomas R. Suozzi (Democratic)Haley M. Stevens (Democratic)Anthony G. Brown (Democratic)Lucille Roybal-Allard (Democratic)Peter A. DeFazio (Democratic)Ro Khanna (Democratic)Maria Elvira Salazar (Republican)Greg Stanton (Democratic)Alan S. Lowenthal (Democratic)Ann M. Kuster (Democratic)Don Bacon (Republican)Fred Upton (Republican)Doris O. Matsui (Democratic)Filemon Vela (Democratic)Glenn Grothman (Republican)Mark Takano (Democratic)Eleanor Holmes Norton (Democratic)Jamie Raskin (Democratic)Cynthia Axne (Democratic)James P. McGovern (Democratic)Maxine Waters (Democratic)William R. Keating (Democratic)Marie Newman (Democratic)Adam Kinzinger (Republican)Peter Welch (Democratic)Brian K. Fitzpatrick (Republican)Bill Posey (Republican)Nanette Diaz Barragán (Democratic)Teresa Leger Fernandez (Democratic)Rashida Tlaib (Democratic)Grace F. Napolitano (Democratic)Susan Wild (Democratic)Judy Chu (Democratic)

Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee

Health

Related Bills

  • S 117-1692: Concentrating on High-Value Alzheimer’s Needs to Get to an End (CHANGE) Act of 2021
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
AgingCongressional oversightGovernment studies and investigationsHealth care costs and insuranceHealth care qualityHealth information and medical recordsHealth promotion and preventive careMedical researchMedical tests and diagnostic methodsMedicareNeurological disordersPublic-private cooperationResearch administration and funding